Study of Natural Killer Cells in Bone Marrow and Blood Samples From Patients With and Without Hematologic Cancer

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Collecting and storing samples of bone marrow and blood from patients with cancer to study in the laboratory may help doctors find better ways to treat the cancer. PURPOSE: This research study is looking at natural killer cells in bone marrow and blood samples from patients with hematologic cancer and from patients who do not have cancer.

Detailed Description
-----------------
OBJECTIVES: To collect normal and malignant cells in bone marrow and peripheral blood samples from patients with acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, or multiple myeloma and from patients with no malignancy to use as target cells in cytotoxicity assays. To collect information about HLA type and immunophenotype of malignant cells as determined by clinical flow cytometry. OUTLINE: Bone marrow aspirates and/or peripheral blood samples are collected and used as target cells in standard cytotoxicity assays, with notch-induced natural killer (N-NK) cells as the effector cells, to determine whether N-NK cells are capable of killing malignant cells and/or non-malignant cells. Receptor-blocking antibodies may be added to determine which NK cell receptors are responsible for malignant cell recognition and killing. Information about HLA type and immunophenotype of the malignant cells is collected from the patient's medical record.

Official Title
-----------------
Collection of Bone Marrow and Peripheral Blood for Testing of Notch-induced Natural Killer Cell Activity

Conditions
-----------------
Leukemia, Multiple Myeloma and Plasma Cell Neoplasm

Intervention / Treatment
-----------------
* Other: biologic sample preservation procedure
* Other: immunologic technique
* Other: laboratory biomarker analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Meets one of the following criteria: No evidence of malignancy Diagnosis of one of the following: Acute myeloid leukemia Acute lymphoblastic leukemia Chronic myelogenous leukemia Multiple myeloma PATIENT CHARACTERISTICS: Not specified PRIOR CONCURRENT THERAPY: Not specified
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with hematologic cancer<br>Patients with acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, or multiple myeloma | Other: biologic sample preservation procedure<br>* All specimens will be collected using the Pathology Residual Tissue Procurement.<br>Other: immunologic technique<br>* Information about HLA type and immunophenotype of the malignant cells is collected from the patient's medical record.<br>Other: laboratory biomarker analysis<br>* Bone marrow aspirates and/or peripheral blood samples are collected and used as target cells in standard cytotoxicity assays, with notch-induced natural killer (N-NK) cells as the effector cells, to determine whether N-NK cells are capable of killing malignant cells and/or non-malignant cells. Receptor-blocking antibodies may be added to determine which NK cell receptors are responsible for malignant cell recognition and killing.<br>|
| Patients without cancer<br>Patients who do not have cancer. | Other: biologic sample preservation procedure<br>* All specimens will be collected using the Pathology Residual Tissue Procurement.<br>Other: immunologic technique<br>* Information about HLA type and immunophenotype of the malignant cells is collected from the patient's medical record.<br>Other: laboratory biomarker analysis<br>* Bone marrow aspirates and/or peripheral blood samples are collected and used as target cells in standard cytotoxicity assays, with notch-induced natural killer (N-NK) cells as the effector cells, to determine whether N-NK cells are capable of killing malignant cells and/or non-malignant cells. Receptor-blocking antibodies may be added to determine which NK cell receptors are responsible for malignant cell recognition and killing.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Collection of normal and malignant cells to use as target cells in cytotoxicity assays |  | We anticipate collecting approximately 30 samples in total, over a 1-2 year period. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
childhood chronic myelogenous leukemia, chronic myelogenous leukemia, adult acute lymphoblastic leukemia, childhood acute lymphoblastic leukemia, adult acute myeloid leukemia, childhood acute myeloid leukemia/other myeloid malignancies, multiple myeloma